Quintiles expands CRO partnership in Indonesia
Signs two-year agreement with Prodia in Jakarta
Quintiles is expanding its partnership with a contract research organisation (CRO) in Indonesia to facilitate rapid testing of samples from patients in clinical trials.
The two-year agreement provides Quintiles with exclusive access to a central facility at Prodia Clinical Laboratory in Jakarta.
‘Major health issues in Indonesia’s ethnically diverse population of 240 million include infectious and non-communicable diseases, with tobacco-related illnesses also on the rise,’ said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines.
‘As new and improved medicines are developed for these conditions, it’s important that they are studied in populations for whom they are intended, including Indonesian patients.’
Prodia was the first clinical laboratory in Indonesia to meet with ISO 9001 & ISO 15189 standards, and has recently obtained certification from the National Glycohemoglobin Standardization Program (NGSP) Level 1 for HbA1c standardization, and is in the process of accreditation by the College of American Pathologists.